GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » Cyclically Adjusted PB Ratio

Aldeyra Therapeutics (STU:137) Cyclically Adjusted PB Ratio : 1.40 (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aldeyra Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Aldeyra Therapeutics's current share price is €3.533. Aldeyra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.52. Aldeyra Therapeutics's Cyclically Adjusted PB Ratio for today is 1.40.

The historical rank and industry rank for Aldeyra Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:137' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 17.67
Current: 1.41

During the past years, Aldeyra Therapeutics's highest Cyclically Adjusted PB Ratio was 17.67. The lowest was 0.00. And the median was 0.00.

STU:137's Cyclically Adjusted PB Ratio is ranked better than
55.64% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs STU:137: 1.41

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aldeyra Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €1.756. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.52 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aldeyra Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Aldeyra Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Cyclically Adjusted PB Ratio Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 25.75 1.47

Aldeyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.31 22.19 3.18 1.47 1.20

Competitive Comparison of Aldeyra Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Aldeyra Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Cyclically Adjusted PB Ratio falls into.



Aldeyra Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aldeyra Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=3.533/2.52
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aldeyra Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.756/131.7762*131.7762
=1.756

Current CPI (Mar. 2024) = 131.7762.

Aldeyra Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.298 100.560 1.701
201409 1.152 100.428 1.512
201412 0.916 99.070 1.218
201503 1.854 99.621 2.452
201506 2.892 100.684 3.785
201509 2.632 100.392 3.455
201512 2.351 99.792 3.105
201603 1.898 100.470 2.489
201606 2.106 101.688 2.729
201609 1.820 101.861 2.355
201612 1.632 101.863 2.111
201703 1.730 102.862 2.216
201706 1.371 103.349 1.748
201709 2.015 104.136 2.550
201712 1.749 104.011 2.216
201803 1.485 105.290 1.859
201806 1.519 106.317 1.883
201809 1.168 106.507 1.445
201812 2.901 105.998 3.607
201903 2.581 107.251 3.171
201906 2.208 108.070 2.692
201909 1.701 108.329 2.069
201912 1.510 108.420 1.835
202003 1.333 108.902 1.613
202006 1.421 108.767 1.722
202009 1.520 109.815 1.824
202012 1.265 109.897 1.517
202103 2.222 111.754 2.620
202106 3.344 114.631 3.844
202109 3.217 115.734 3.663
202112 3.135 117.630 3.512
202203 2.970 121.301 3.226
202206 2.824 125.017 2.977
202209 2.797 125.227 2.943
202212 2.434 125.222 2.561
202303 2.180 127.348 2.256
202306 2.039 128.729 2.087
202309 1.947 129.860 1.976
202312 1.856 129.419 1.890
202403 1.756 131.776 1.756

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aldeyra Therapeutics  (STU:137) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aldeyra Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics (STU:137) Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (STU:137) Headlines

No Headlines